AI Longevity Is Booming in Asia but Only for the Rich

The $27 Trillion Longevity Economy Has an Asia Problem

Across Asia-Pacific, a new class of health service is emerging at the intersection of artificial intelligence, genomics, and old-fashioned wealth. AI-powered longevity clinics are spreading through Hong Kong, Singapore, and Tokyo, promising to extend healthspan through personalised diagnostics, epigenetic testing, and real-time biometric coaching. The catch: most people cannot afford any of it.

The global longevity economy is projected to reach $27 trillion in 2026, according to the Aging Analytics Agency. Asia-Pacific accounts for nearly 60% of the world's ageing population. The demand is real. But the supply is overwhelmingly targeted at the wealthy.

What the Clinics Actually Offer

Hong Kong's Prenetics, which went public via SPAC in 2022, now offers CircleDNA premium packages that include AI-generated health reports and personalised supplement recommendations. The service analyses over 500 genetic markers and uses machine learning to map risk profiles for conditions ranging from cardiovascular disease to nutrient deficiencies.

In Singapore, Chi Longevity Centre takes it further. The clinic uses epigenetic testing and AI to build personalised healthspan plans, adjusting regimens in real time based on wearable data and bloodwork. A full programme reportedly costs upwards of $15,000 per year.

Tokyo's Euglena subsidiary MyHealth focuses on AI-powered gut microbiome analysis, correlating bacterial diversity with ageing markers to recommend dietary and lifestyle interventions. Japan's ageing demographics, with nearly 30% of the population over 65, make it a natural market for longevity services.

"As ageing accelerates across Asia and worldwide, the convergence of biotechnology, digital health, and artificial intelligence is poised to reshape the longevity landscape fundamentally." - Jamie Gibson, CEO, Regent Pacific Group

Deep Longevity and the Ageing Clock

Deep Longevity, part of the Regent Pacific portfolio, is deploying AI-powered "ageing clocks" across healthcare diagnostics, corporate wellness programmes, insurance, and medical aesthetics. Products like FaceAge and MicrobiomeAge use machine learning to estimate biological age from photographs and gut bacteria profiles respectively.

The company has signed SaaS contracts and pilot arrangements with partners across Asia, the United States, and the Middle East. Hong Kong's 2025 Policy Address explicitly prioritised emerging industries including life and health technology and AI, creating regulatory tailwinds for companies like Deep Longevity.

The Access Gap

Here is the tension. Asia has the world's largest ageing population and the fastest-growing AI healthcare market. But the services being built are priced for the top 1%. A CircleDNA premium report costs several hundred dollars. A year at Chi Longevity costs more than the median annual income in most of Southeast Asia.

"75% of Asia-Pacific healthcare providers expect greater productivity gains from agentic AI than GenAI without agents. The technology exists to democratise these services, but the business models have not caught up." - IDC Asia-Pacific Healthcare FutureScape 2026

The telemedicine market in Asia-Pacific is expected to double from $40.6 billion in 2025 to $80.4 billion by 2030. Wearables from Xiaomi, Huawei, and Samsung are bringing biometric tracking to mass-market price points. But there is a growing gulf between what consumer wearables can tell you (your heart rate is elevated) and what a longevity clinic can do about it (here is your personalised epigenetic intervention plan).

Provider	Location	Core AI Service	Approximate Annual Cost
Prenetics CircleDNA	Hong Kong	Genomic analysis + AI health reports	$200-$600 per report
Chi Longevity Centre	Singapore	Epigenetic testing + real-time AI coaching	$15,000+
Euglena MyHealth	Tokyo	Gut microbiome analysis + AI dietary plans	$500-$1,200
Deep Longevity	Hong Kong	Ageing clocks (FaceAge, MicrobiomeAge)	$150-$400 per assessment
Consumer wearables	Region-wide	Heart rate, SpO2, sleep tracking	$50-$500 (device cost)

Where the Money Is Going

India, China, and Japan account for the largest share of longevity-focused companies globally. India represents 30.7% of the 1,727 longevity companies tracked by Aging Analytics Agency, China 20.6%, and Japan 7.2%. Investment is flowing into AI-powered drug discovery, personalised nutrition, and preventive diagnostics.

China's 15th Five-Year Plan has explicitly prioritised AI-driven longevity technologies, and the country's ageing demographics make it both the largest market and the most urgent policy challenge. By 2035, more than 400 million Chinese citizens will be over 60.

Can AI Longevity Scale Beyond the Wealthy?

The optimistic case is that costs will fall as AI models improve and data pools grow. Genomic sequencing costs have dropped 99% in two decades. Wearable sensors are getting cheaper and more capable every year. The pessimistic case is that longevity services will follow the pattern of concierge medicine everywhere: premium pricing, exclusive access, and a widening health gap between rich and poor.

The World Economic Forum flagged this tension in January 2026, noting that Asia is entering a longevity era but needs to rethink how wealth and health intersect if the benefits are to reach beyond the elite.

The AIinASIA View: We see a fundamental contradiction in Asia's AI longevity market. The technology is genuinely impressive. AI ageing clocks, epigenetic coaching, and personalised microbiome analysis represent real advances in preventive health. But the business models are designed for wealth management clients, not public health. The companies that figure out how to deliver even a fraction of these insights at mass-market price points, through employer wellness programmes, public health systems, or insurance partnerships, will capture the largest addressable market in healthcare history. Asia has both the demographics and the technology. What it lacks is the distribution model.

Are AI longevity services actually effective?

Early evidence is promising but limited. Biological age assessments can identify risk factors years before symptoms appear. Whether the interventions recommended by AI systems meaningfully extend lifespan is still being studied in longitudinal trials.

Can wearables replace clinic-based longevity services?

Not yet. Consumer wearables excel at tracking activity and basic vitals, but they cannot perform genomic analysis, epigenetic testing, or blood biomarker interpretation. The gap is narrowing as sensors improve, but clinical-grade diagnostics remain a different category.

Which Asian countries are regulating AI health services?

Singapore's Health Sciences Authority and Japan's PMDA both have frameworks for AI-assisted medical devices. Hong Kong's regulatory environment is lighter, which partly explains why many longevity startups base themselves there. Regulatory clarity is still evolving across the region.

Should governments subsidise AI longevity services the way they subsidise basic healthcare, or is personalised healthspan optimisation a luxury that individuals should pay for themselves? Drop your take in the comments below.

YOUR TAKE

We cover the story. You tell us what it means on the ground.